Triamcinolone affects OCT reflectivity in DME

Article

Patients who receive triamcinolone acetonide treatment for DME demonstrate changes in OCT reflectivity in their foveal cystoid spaces that are associated with a rebound in macular thickening and visual deterioration.

Patients who receive triamcinolone acetonide treatment for diabetic macular oedema (DME) demonstrate changes in optical coherence tomography (OCT) reflectivity in their foveal cystoid spaces that are associated with a rebound in macular thickening and visual deterioration, according to a study published in Retina.

Japanese researchers conducted a retrospective review of 58 consecutive eyes treated with triamcinolone acetonide for DME, administered either intravitreally or by sub-Tenon's injection. The researchers circumscribed the foveal cystoid spaces within the eyes’ central 1 mm, and investigated the correlation between OCT reflectivity and visual outcome.

At 1 month after treatment, they found an increase of OCT reflectivity levels in the foveal cystoid spaces, but this increase did not persist at 3 months or 6 months postoperatively.

From 1–6 months and from 3–6 months there was a negative correlation of preoperative reflectivity levels with logMAR changes, but no such correlation was found when comparing the preoperative logMAR with the logMAR at individual postoperative time points.

At 1–6 months postoperatively the changes in foveal thickness correlated negatively with the baseline reflectivity. The foveal thickness changes correlated positively with logMAR changes from 1–6 months and from 3–6 months postoperatively.

To read the abstract of the study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.